While immune-targeting therapies in development are designed to cross the blood–brain barrier to target microglial cells within the brain, future work may clarify whether modulating TREM2, CD33, or PU.1 signaling in the periphery alone may be beneficial in AD [15]. The gene discussed is CD33; the disease is Alzheimer disease.